EMRs are the future: What is "Meaningful Use"?
Most busy oncologists will never have time or patience to sift through the 864-page final rule CMS released Tuesday describing how health care providers can demonstrate "meaningful use" of electronic health records to qualify for Medicare and Medicaid incentive payments under the 2009 federal stimulus package.
Most busy oncologists will never have time or patience to sift through the 864-page final rule CMS released Tuesday describing how health care providers can demonstrate "meaningful use" of electronic health records to qualify for Medicare and Medicaid incentive payments under the 2009 federal stimulus package.
The rule comes exactly 6 months after CMS published a Notice of Proposed Rulemaking on meaningful use. Federal officials received more than 2,000 comments on the proposed rule, often getting conflicting advice.
Some health provider groups-such as the American Hospital Association and the American Medical Association-argued that the proposed rules were unreachable for most health care providers and needed to be relaxed. On the other hand, consumer groups-such as the National Partnership for Women & Families and AARP-urged federal health officials to maintain the high bar of the proposed rule. Even lawmakers weighed in, offering recommendations on how to improve upon the proposal.
In any event, it’s important for the oncology community to keep abreast of the EHR initiative, which, in its various stages of deployment, will affect your practice’s bottom line and operating systems.
Check out this Webinar:
Sage Webinar: Understanding the "Meaningful Use" Final Rule
Please join us for a review of the "Meaningful Use" final rule, as released by the Centers for Medicare and Medicaid Services (CMS). Moderator, Elizabeth W. Woodcock, MBA, FACMPE, CPC, and panelists Betty Otter-Nickerson, Michael Burger and Brenda Pawlak will discuss the "Meaningful Use" incentives and how technology will fuel healthcare reform. We'll also answer your questions during a live Q&A session.
Date: Tuesday, August 10
Time: Noon - 1:00 pm ET
Cost: No charge
Register now
Learn more about this webinar: http://www.sagehealth.com/government_initiatives/economic_stimulus_center/Pages/Understanding_The_Meaningful_Use_Final_Rule.aspx
Targeted Therapy First Strategy Reduces Need for Chemotherapy in Newly Diagnosed LBCL
December 7th 2025Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone may allow 57% of patients with newly diagnosed LBCL to receive less than the standard number of chemotherapy cycles without compromising curative potential.
